NF-κB signaling, liver disease and hepatoprotective agents
Abstract
The NF-kappaB signaling pathway has particular relevance to several liver diseases including hepatitis (liver infection by Helicobacter, viral hepatitis induced by HBV and HCV), liver fibrosis and cirrhosis and hepatocellular carcinoma. Furthermore, the NF-kappaB signaling pathway is a potential target for development of hepatoprotective agents. Several types of drugs including: selective estrogen receptor modulators (SERMs), antioxidants, proteasome inhibitors, IKK inhibitors and nucleic acid-based decoys have been shown to interfere with NF-kappaB activity at different levels and may be useful for the treatment of liver diseases. However, NF-kappaB also plays an important hepatoprotective function that needs to be taken into consideration during development of new therapeutic regimens.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
NF-κB signaling is activated following liver injury and is closely linked to JAK/STAT and PI3K/Akt/mTOR pathways, which regulate hepatocyte proliferation and survival.
“The NF-κB signalling pathway is activated following liver injury and is closely linked to the Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) and phosphoinositide 3-kinase/protein kinase B, PKB/mammalian target of rapamycin pathways, which regulate hepatocyte proliferation and survival mechanisms[53].”
From Liver regeneration after partial hepatectomy: Triggers and mechanisms (2025) · cites this paper as [53]
Cites
Missing Pieces in the NF-κB Puzzle
Ghosh, S., & Karin, M. (2002) · Cell · doi:10.1016/s0092-8674(02)00703-1 · Cited by 3,638 · cited 14× · see citing works
“In both cases, the necrotic death of hepatocytes was found to result in the release of IL-1a, which then activates MyD88-dependent NF-kB signaling in Kupffer cells, leading to IL-6 induction (Sakurai et al., 2008).”
InfluentialSelf-citationThe complete genome sequence of the gastric pathogen Helicobacter pylori
Tomb, J.-F., White, O., Kerlavage, A. R., Clayton, R. A., Sutton, G. G., Fleischmann, R. D., Ketchum, K. A., Klenk, H. P., Gill, S., Dougherty, B. A., et al. (1997) · Nature · doi:10.1038/41483 · Cited by 3,529 · see citing works
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519 · see citing works
Self-citationInduction of TNF receptor I-mediated apoptosis via two sequential signaling complexes
Micheau, O., & Tschopp, J. (2003) · Cell · doi:10.1016/s0092-8674(03)00521-x · Cited by 2,738 · see citing works
Alm, R. A., Ling, L.-S. L., Moir, D. T., King, B. L., Brown, E. D., Doig, P. C., Smith, D. R., Noonan, B., Guild, B. C., deJonge, B. L., et al. (1999) · Nature · doi:10.1038/16495 · Cited by 1,893 · see citing works
NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1α
Rius, J., Guma, M., Schachtrup, C., Akassoglou, K., Zinkernagel, A. S., Nizet, V., Johnson, R. S., Haddad, G. G., & Karin, M. (2008) · Nature · doi:10.1038/nature06905 · Cited by 1,614 · see citing works
Self-citationYamada, Y., Kirillova, I., Peschon, J. J., & Fausto, N. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.4.1441 · Cited by 944 · see citing works
Chen, C.-J., Kono, H., Golenbock, D., Reed, G., Akira, S., & Rock, K. L. (2007) · Nature Medicine · doi:10.1038/nm1603 · Cited by 876 · see citing works
Sulfasalazine: A potent and specific inhibitor of nuclear factor kappa B
Wahl, C., Liptay, S., Adler, G., & Schmid, R. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci992 · Cited by 742 · see citing works
Chang, L., Kamata, H., Solinas, G., Luo, J.-L., Maeda, S., Venuprasad, K., Liu, Y.-C., & Karin, M. (2006) · Cell · doi:10.1016/j.cell.2006.01.021 · Cited by 706 · see citing works
Self-citationHepatic T cells and liver tolerance
Crispe, I. N. (2003) · Nature Reviews Immunology · doi:10.1038/nri981 · Cited by 661 · see citing works
IKKβ Is Required for Prevention of Apoptosis Mediated by Cell-Bound but Not by Circulating TNFα
Maeda, S., Chang, L., Li, Z.-W., Luo, J.-L., Leffert, H., & Karin, M. (2003) · Immunity · doi:10.1016/s1074-7613(03)00301-7 · Cited by 286 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Godoy, P., Hewitt, N. J., Albrecht, U., Andersen, M. E., Ansari, N., Bhattacharya, S., Bode, J. G., Bolleyn, J., Borner, C., Böttger, J., et al. (2013) · Archives of Toxicology · doi:10.1007/s00204-013-1078-5 · Cited by 1,280 · see citing works
Mechanisms of liver disease: cross-talk between the NF-κB and JNK pathways
Papa, S., Bubici, C., Zazzeroni, F., & Franzoso, G. (2009) · bchm · doi:10.1515/bc.2009.111 · Cited by 156 · see citing works
Kondylis, V., Polykratis, A., Ehlken, H., Ochoa-Callejero, L., Straub, B. K., Krishna-Subramanian, S., Van, T.-M., Curth, H.-M., Heise, N., Weih, F., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.001 · Cited by 131 · see citing works
Heida, A., Gruben, N., Catrysse, L., Koehorst, M., Koster, M., Kloosterhuis, N. J., Gerding, A., Havinga, R., Bloks, V. W., Bongiovanni, L., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101349 · Cited by 78 · see citing works
Liver regeneration after partial hepatectomy: Triggers and mechanisms
Korchilava, B., Khachidze, T., Megrelishvili, N., Svanadze, L., Kakabadze, M., Tsomaia, K., Jintcharadze, M., & Kordzaia, D. (2025) · World Journal of Hepatology · doi:10.4254/wjh.v17.i7.107378 · Cited by 21 · see citing works
- Authors
- Sun, B., & Karin, M.
- Affiliations
- Nanjing Medical University (CN)
- University of California San Diego (US)
- Corresponding author
- Karin, M
- Venue
- Oncogene
- Published
- 2008-10-20
- Volume
- 27
- Issue
- 48
- Pages
- 6228-6244
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2006626994
- Cited by
- 307
- References
- 12
- Citations by year
- 2026: 9 · 2025: 10 · 2024: 14 · 2023: 17 · 2022: 23 · 2021: 21 · 2020: 23 · 2019: 12 · 2018: 17 · 2017: 16 · 2016: 16 · 2015: 20 · 2014: 18 · 2013: 21 · 2012: 15
- FWCI
- 1.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- National Natural Science Foundation of China
- Government of Jiangsu Province
- Centers for Disease Control and Prevention
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › NF-κB Signaling Pathways
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- NF-κB signaling, liver disease, hepatoprotective agents, hepatitis, liver fibrosis, liver cirrhosis, hepatocellular carcinoma, selective estrogen receptor modulators, antioxidants, proteasome inhibitors, IKK inhibitor, Helicobacter, hepatitis B virus, hepatitis C virus
- MeSH terms
- Humans, Liver Diseases, Signal Transduction, NF-kappa B
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
